Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Summary

The current study aims to explore the potential advantages of anti-cancer therapy that is implemented based on drug sensitivity testing. This pertains to individuals with locally advanced thyroid cancer who have undergone conventional therapy in the past or unresectable patients .

Eligibility

Inclusion Criteria:

* 1\. Adult participants who have either been initially diagnosed with locally advanced thyroid cancer or have experienced persistent or recurrent thyroid cancer, including cervical nodal recurrence. Types of pathology include:

  1. Papillary thyroid carcinoma (PTC)
  2. Follicular thyroid carcinoma (FTC)
  3. Medullary thyroid carcinoma (MTC)
  4. Poorly differentiated thyroid carcinoma (PDTC)
  5. Anaplastic thyroid carcinoma (ATC)
* 2\. Evidence of extrathyroidal extension and/or locally invasive disease and deemed at risk for R2 resection by treating team on clinical and/or fiberoptic examination and/or radiographic evaluation in the primary or recurrent setting. Evidence of "at risk for R2 resection" includes:

  1. Vocal cord paralysis by fiberoptic examination
  2. Extrathyroid and/or extranodal extension on CT or MRI, including tracheal and/or laryngeal cartilage invasion, esophageal involvement, and/or involvement of perithyroid muscles (e.g. strap, sternocleidomastoid, inferior constrictor muscles) or bone involvement
  3. Extension into the mediastinum with visceral and/or vascular involvement
  4. Involvement of the carotid artery or other major vessel by 180 degrees or more
  5. Other factors that make the participant to be "at risk for R2 resection" may be allowed, after discussion with the study's principal investigator.
* 3\. There is at least one measurable lesion according to the Modified Response Evaluation Criteria in Solid Tumors (mRECIST).
* 4\. Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
* 5\. Normal organ and bone marrow function.
* 6\. Adequate end-organ function (including bone marrow, coagulation, renal, liver and cardiac) 28 days prior to the study registration.
* 7\. Ability to swallow pills.
* 8\. Signed informed consent form.
* 9\. Expected survival time of more than 2 months.

Exclusion Criteria:

* 1\. Patients with contraindications specified in the drug instructions for the targeted drugs involved in the corresponding organoid drug sensitivity tests.
* 2\. Patients with incomplete clinical data.
* 3\. Patients with severe organ dysfunction, metabolic diseases, or other conditions significantly affecting survival.
* 4\. Other active malignant disease requiring therapy.
* 5\. Females who are pregnant or breastfeeding.
* 5\. Patients without target lesions.
* 6\. Patients deemed unsuitable for inclusion by the researchers.

Conditions2

Interventions12

Related trials

• A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy — Zhejiang Cancer Hospital
• A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma — Army Medical Center of PLA
• Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma — Guangdong Provincial People's Hospital
• Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer — Hunan Province Tumor Hospital
• Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients. — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer — Fudan University
• Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer — Zhongnan Hospital

Browse More Trials